Clinical Trials
38 trialsNCT01541709 2024-01-02
Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI
Asan Medical Center
Phase 2 Unknown
NCT03193281 2023-11-29
KISS
University of Auckland, New Zealand
Phase 2 Unknown
NCT04546074 2023-10-03
Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma
Keio University
Phase 1/2 Unknown
NCT02365441 2023-07-07
ALT GIST
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT04138381 2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Unknown
NCT02461849 2022-06-15
Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy
Samsung Medical Center
Phase 2 Unknown
NCT02602314 2022-01-20
SUSTRENIM
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 4 Unknown
NCT04688983 2020-12-30
EWALL-Ph-03
Cardiff University
Phase 2 Unknown
NCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT03862768 2019-03-05
Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment
Shanghai Zhongshan Hospital
Phase NA Unknown
NCT03515018 2018-05-22
HU
First Affiliated Hospital of Harbin Medical University
Phase 3 Unknown
NCT03228303 2017-10-10
Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia
Assiut University
Phase EARLY_PHASE1 Unknown
NCT03241199 2017-08-08
The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia
The University of Hong Kong
Phase 2 Unknown
NCT02894645 2016-09-30
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
National University Hospital, Singapore
Phase 4 Unknown
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT02687425 2016-02-22
SESPI
Tongji Hospital
Phase 2 Unknown
NCT02576080 2015-10-15
GIGIST
Assistance Publique Hopitaux De Marseille
Phase 3 Unknown
NCT02317159 2014-12-15
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Cttq
Phase 4 Unknown
NCT00685828 2014-07-04
Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Unknown
NCT01400074 2014-01-13
RE-NICE
Seoul St. Mary's Hospital
Phase 3 Unknown
NCT01005758 2014-01-10
Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00028847 2013-09-17
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1/2 Unknown
NCT00904735 2013-08-12
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT01503502 2013-04-10
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT01221376 2013-03-26
Phase II Study for Safety and Efficacy Evaluation of Imatinib Mesylate in Children With Chronic Myeloid Leukemia (CML) Philadelphia Chromosome-positive (Ph+)
Hospital Santa Marcelina
Phase 2 Unknown
NCT01782508 2013-02-04
A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01175109 2012-12-27
Study of Imatinib, a Platelet-derived Growth Factor Receptor Inhibitor, and LBH589, a Histone Deacetylase Inhibitor, in the Treatment of Newly Diagnosed and Recurrent Chordoma
University of Virginia
Phase 1 Unknown
NCT01227135 2011-11-30
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
Phase 2 Unknown
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00551252 2007-10-30
A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
Gruppo Italiano MEsotelioma
Phase 2 Unknown
NCT00199186 2007-10-19
Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)
Johann Wolfgang Goethe University Hospital
Phase 2 Unknown
NCT00297570 2007-10-10
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Sheba Medical Center
Phase 3 Unknown
NCT00180921 2007-09-26
Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT00146913 2007-04-27
AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One Year
Hospices Civils de Lyon
Phase 2 Unknown
NCT00149136 2007-04-27
Treatment of Philadelphia-Positive Acute Lymphocytic Leukemia (Ph+ ALL) in the Elderly With Imatinib Mesylate (STI571) and Chemotherapy.
Hospices Civils de Lyon
Phase 2 Unknown
NCT00327262 2006-06-20
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Central European Leukemia Study Group
Phase 3 Unknown
NCT00290485 2006-04-07
Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST)
Maisonneuve-Rosemont Hospital
Phase 2 Unknown